Skip to Content

Are you based in North America? If yes, switch to our North American website →

IGH/MYC Translocation, Dual Fusion

Applications
haematopathology
Catalogue Numbers
LPS 035 (10 tests)
LPS 035-S (5 tests)

The cMYC/IGH translocation, t(8;14)(q24;q32), and the variant forms t(2;8)(p13;q24) and t(8;22)(q24;q11) are found in Burkitt's lymphoma and mature B-cell or Burkitt's type Acute Lymphoblastic Leukaemia (ALL)1.

The t(8;14) is the most common and is found in approximately 85% of patients with Burkitt's lymphoma2. While translocation breakpoints on chromosome 14 are clustered to a narrow region 5' to the intron enhancer of the immunoglobulin heavy chain, the breakpoints on chromosome 8 can occur more than 340kb upstream of MYC, with no preferential site3. The translocation brings MYC into close proximity to the IgH enhancer and results in the up-regulation of MYC4. Over expression of the transcription factor stimulates gene amplification resulting in uncontrolled cell proliferation, which usually occurs in the late event of tumour progression5.

References

1. Berger R, Bernheim A, Cancer Genet Cytogenet 1982;7(3):231-44

2. Hoffman, Ronald (2009). Hematology : basic principles and practice (5th ed. ed.). Philadelphia, PA: ChurchillLiving stone/Elsevier. pp. 1304–1305

3. Joos et al., Human Molecular Genetics 1992;1(8):625-32

4. Erikson J et al., Proc Natl Acad Sci USA 1983;80(3):820-4

5. Shou et al., PNAS 2000;97(1):228-33

Microscope Images

IGH MYC Translocation Dual Fusion magnified
Area of Interest*
Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples, or formalin-fixed paraffin-embedded (FFPE) tissues.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.